

# SAFETY DATA SHEET

### SECTION 1: IDENTIFICATION

Product Name: Mesna Injection Manufacturer Name: Fresenius Kabi USA, LLC Address: Three Corporate Drive Lake Zurich, Illinois 60047

General Phone Number: (847) 550-2300 Customer Service Phone (888) 386-1300 Number:

Health Issues Information: (800) 551-7176 SDS Creation Date: January 08, 2009 SDS Revision Date: June 01, 2015

(M)SDS Format:

### SECTION 2: HAZARD(S) IDENTIFICATION

GHS Pictograms:







Signal Word: DANGER.

GHS Class: Serious Eye Damage. Category 1.

Skin corrosion. Category 1.
Respiratory sensitisation. Category 1.

Skin Sensitization. Category 1. Reproductive toxicity. Effects on or via lactation.

Hazard Statements: Causes serious eye damage.

Causes severe skin burns and eye damage.
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

May cause an allergic skin reaction. May cause harm to breast-fed children.

Precautionary Statements: Obtain special instructions before use.

Do not breathe dust/fume/gas/mist/vapours/spray. Avoid breathing dust/fume/gas/mist/vapours/spray. Avoid contact during pregnancy and while nursing. Wash hands thoroughly after handling. Do not eat, drink or smoke when using this product.

Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves/protective clothing/eye protection/face protection.

In case of inadequate ventilation wear respiratory protection. IF SWALLOWED: Rinse mouth. Do not induce vomiting.

IF ON SKIN: Wash with plenty of water.
IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with

water/shower.

IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy

to do. Continue rinsing.

IF exposed or concerned: Get medical advice/attention.

Immediately call a POISON CENTER or doctor/physician Specific treatment (see ... on this label).

If skin irritation or rash occurs: Get medical advice/attention.

If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician.

Take off contaminated clothing and wash it before reuse.

Wash contaminated clothing before reuse.

Store locked up.
Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations.

This product is intended for therapeutic use only when prescribed by a physician. Potential adverse Emergency Overview:

reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eve: Contact with eves may cause irritation.

Adverse reactions from therapeutic doses include: headache, fatigue, nausea, diarrhea, limb pain, hypotension, and vomiting. Allergic reaction may also occur. Occupational exposure has not been fully Signs/Symptoms:

investigated

Aggravation of Pre-Existing

Individuals with known hypersensitivity to mesna or any other thiol compounds or pre-existing skin and

respiratory conditions

# SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

**Chemical Name** CAS# **Ingredient Percent** EC Num.

Mesna Injection Revision: 06/01/2015 Fresenius Kabi USA, LLC

Mesna 19767-45-4 100 ma/mL Benzyl Alcohol 100-51-6 10.4 mg/mL Edetate Disodium 139-33-3 0.25 ma/mL

### SECTION 4: FIRST AID MEASURES

Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of Eve Contact:

the eyes by separating the eyelids with fingers. Get immediate medical attention

Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Skin Contact:

Get medical attention if irritation develops or persists.

If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention. Inhalation:

If conscious, flush mouth out with water immediately. Call a physician or poison control center immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Ingestion:

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

#### SECTION 5: FIRE FIGHTING MEASURES

Flash Point: Not established Flash Point Method: Not established. Auto Ignition Temperature: Not established Lower Flammable/Explosive Limit: Not established. Upper Flammable/Explosive Limit: Not established

Fire Fighting Instructions: Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to

minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible,

contain fire run-off water.

Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires

Use  $\operatorname{ext}$  inguishing measures that are appropriate to local circumstances and the surrounding environment.

As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent) and full protective gear. Protective Equipment:

Hazardous Combustion

Byproducts:

Thermal decomposition products may include smoke and toxic fumes. Oxides of carbon, oxides of nitrogen and other organic substances may be formed. Other undetermined low molecular weight hydrocarbon compounds may be released in small quantities depending upon specific conditions of

combustion

### SECTION 6: ACCIDENTAL RELEASE MEASURES

Personnel Precautions: Evacuate area and keep unnecessary and unprotected personnel from entering the spill area.

Avoid personal contact and breathing vapors or mists. Use proper personal protective equipment as

listed in Section 8.

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods for containment: Contain spills with an inert absorbent material such as soil, sand or oil dry.

Methods for cleanup: Absorb spill with inert material (e,g., dry sand or earth), then place in a chemical waste container. After

removal, flush spill area with soap and water to remove trace residue.

## SECTION 7: HANDLING and STORAGE

When handling pharmaceutical products, avoid all contact and inhalation of vapor, mists and/or fumes. Use with adequate ventilation. Use only in accordance with directions. Handling:

Storage: Store at controlled room temperature 20 to 25°C (68 to 77°F). [See USP Controlled Room

Temperature]

Work Practices: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety

Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling vapor or mist. Hygiene Practices:

## SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

**Engineering Controls:** General ventilation is sufficient if this product is being used in a controlled medical setting (clinic,

hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended exposure limits.

Eye/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist.

Fresenius Kabi USA, LLC

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Hand Protection Description: Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data.

Nitrile rubber or natural rubber gloves are recommended.

Respiratory Protection:

No personal respiratory protective equipment is normally required when this product is being used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible under certain circumstances. Consult the NIOSH web site

 $(http://www.cdc.gov/niosh/npptl/topics/respirators/) \ for \ a \ list \ of \ respirator \ types \ and \ approved \ suppliers.$ 

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal protective equipment.

#### EXPOSURE GUIDELINES

### SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

Physical State: Liquid solution. Color: Colorless.

Boiling Point: Approximately 100°C

Melting Point:

Solubility: Soluble. in water. Vapor Density: Not established. Vapor Pressure: Not established. Percent Volatile: Not established. pH: 6.5 - 8.5 Molecular Formula: Mixture Molecular Weight: 164.18

Flash Point: Not established. Flash Point Method: Not established. Not established. Auto Ignition Temperature:

# SECTION 10: STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

Hazardous Polymerization: Not reported.

Conditions to Avoid: No conditions contributing to instability are known to exist for normal handling of this product.

### SECTION 11: TOXICOLOGICAL INFORMATION

Acute Toxicity:

Adverse reactions from therapeutic doses include: headache, fatigue, nausea, diarrhea, limb pain, hypotension, and vomiting. Allergic reaction may also occur. Occupational exposure has not been fully

investigated.

Mesna:

LD50 IV Rat: 1510 mg/kg Acute Toxicity:

LD50 IV Mouse: 1720 mg/kg LD50 IP Rat: 1251 mg/kg LD50 IP Mouse: 2005 mg/kg LD50 IM Rat: 2313 mg/kg LD50 IM Mouse: 1200 mg/kg

Acute Effects:

Adverse reactions from therapeutic doses include: headache, fatigue, nausea, diarrhea, limb pain, hypotension, and vomiting. Allergic reaction may also occur. Occupational exposure has not been fully investigated.

Teratogenicity: Pregnancy Category B:

Mesna Injection should be given to a pregnant woman only if the benefits clearly outweigh any possible

risks.

Mesna:

RTECS Number: KI7968000

Ingestion:

Oral - Rat LD50: 4440 mg/kg [Details of toxic effects not reported other than lethal dose value] Oral - Mouse LD50: 6102 mg/kg [Details of toxic effects not reported other than lethal dose value]

Other Toxicological Information: Intravenous. - Rat LD50: 1510 mg/kg [Behavioral - altered sleep time (including change in righting

reflex) Gastrointestinal - ulceration or bleeding from small intestine Nutritional and Gross Metabolic body temperature decrease]

Intravenous. - Mouse LD50: 1720 mg/kg [Behavioral - altered sleep time (including change in righting reflex) Blood - changes in spleen Nutritional and Gross Metabolic - body temperature decrease]
Intravenous. - Rat LD50: 1600 mg/kg [Details of toxic effects not reported other than lethal dose

Intravenous. - Rat TDLo: 17500 mg/kg/35D (continuous) [Lungs, Thorax, or Respiration - changes in lung weight Kidney/Ureter/Bladder - other changes in urine composition Blood - normocytic anemia]
Intravenous. - Rat TDLo: 8800 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - viability index (e.g., number alive at

Mesna Injection Revision: 06/01/2015 day 4 per number born alive) Reproductive - Effects on Newborn - growth statistics (e.g., reduced

weight gain)]
Intravenous. - Rat TDLo: 4400 mg/kg [Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - behavioral]
Intravenous. - Rat TDLo: 10400 mg/kg [Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - physical]
Intravenous. - Rat TDLo: 26880 mg/kg [Reproductive - Maternal Effects - other effects Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Embryo or Fetus - other effects to embryo]
Intravenous. - Rabbit TDLo: 7800 mg/kg [Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal

Subcutaneous - Rat LD50: 2313 mg/kg [Behavioral - altered sleep time (including change in righting reflex) Gastrointestinal - ulceration or bleeding from small intestine Skin and Appendages - hair] Subcutaneous - Mouse LD50: 1200 mg/kg [Details of toxic effects not reported other than lethal dose

Intraperitoneal. - Rat LD50: 1251 mg/kg [Details of toxic effects not reported other than lethal dose

Intraperitoneal. - Mouse LD50: 2005 mg/kg [Details of toxic effects not reported other than lethal dose Intraperitoneal. - Mouse EDSO: 2005 mg/kg [Details of toxic effects not reported other than lethal dose value]
Intraperitoneal. - Rat TDLo: 64.5 mg/kg [Kidney/Ureter/Bladder - other changes Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation]
Intraperitoneal. - Rat TDLo: 6300 mg/kg/SW (intermittent) [Biochemical - Metabolism (Intermediary) -

effect on inflammation or mediation of inflammation]

effect on inflammation or mediation of inflammation]
Intraperitoneal. - Rat TDLo: 72 gm/kg/26W (continuous) [Kidney/Ureter/Bladder - changes in bladder weight Blood - normocytic anemia Related to Chronic Data - changes in prostate weight]
Intraperitoneal. - Mouse TDLo: 48 gm/kg/4W (intermittent) [Related to Chronic Data - death]
Intraperitoneal. - Rat TDLo: 6300 mg/kg/5W (intermittent) [Lungs, Thorax, or Respiration - other changes Blood - changes in platelet count Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects]

#### Benzyl Alcohol:

RTECS Number: DN3150000

Skin: Administration onto the skin - Rabbit LD50: 2000 mg/kg [Details of toxic effects not reported other

than lethal dose value]

than letter dose value; Administration onto the skin - Rabbit Standard Draize test.: 100 mg/24H Administration onto the skin - Rat LD50: 100 pph/90M [Details of toxic effects not reported other than

lethal dose value]

Inhalation:

Inhalation - Mouse LC50: >500 mg/m3 [Behavioral - Somnolence (general depressed activity)
Behavioral - Ataxia Lungs, Thorax, or Respiration - Respiratory depression]
Inhalation - Rat LC50: >500 mg/m3 [Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lungs, Thorax, or Respiration - Respiratory depression]

Oral - Rat LD50: 1230 mg/kg [Behavioral - Somnolence (general depressed activity) Behavioral -Ingestion:

Excitement Behavioral - Coma]
Oral - Mouse LD50: 1360 mg/kg [Details of toxic effects not reported other than lethal dose value] Oral - Mouse LD50: 1360 mg/kg [Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lungs, Thorax, or Respiration - Respiratory depression]
Oral - Rat LD50: 1660 mg/kg [Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lungs, Thorax, or Respiration - Respiratory depression]
Oral - Rat LD50: 1.5 mL/kg [Details of toxic effects not reported other than lethal dose value]

Other Toxicological Information:

Intravenous. - Rat LD50: 53 mg/kg [Lungs, Thorax, or Respiration - dyspnea]
Intravenous. - Mouse LD50: 324 mg/kg [Details of toxic effects not reported other than lethal dose value]

Subcutaneous - Rat LDLo: 1700 mg/kg [Sense Organs and Special Senses (Eye) - miosis (pupillary constriction) Behavioral - coma Kidney/Ureter/Bladder - other changes]

Intraperitoneal. - Rat LD50: 400 mg/kg [Details of toxic effects not reported other than lethal dose

value1 Intraperitoneal. - Mouse LD50: 650 mg/kg [Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Lungs, Thorax, or Respiration -

dvspnea1 Intraperitoneal. - Rat LDLo: 650 mg/kg [Behavioral - somnolence (general depressed activity)

Behavioral - ataxia Lungs, Thorax, or Respiration - respiratory depression] Intraperitoneal. - Rat TDLo: 514 mg/kg [Behavioral - ataxia]

# **Edetate Disodium:**

RTECS Number: AH4375000

Eye: Rabbit, not irritating Skin: Rabbit, not irritating.

Inhalation: Inhalation - Rat LOAEC 30 mg/m3/6 h (aerosol) (OECD Guideline 412) (ECHA)

Ingestion: Oral - Rat LD50 2800 mg/kg (ECHA)

Other Toxicological Information: Intravenous. - Mouse LD50 : 56 mg/kg (RTEC)

# SECTION 12: ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product

Environmental Stability: No environmental information found for this product.

**Edetate Disodium:** 

Ecotoxicity:

Guppy (Poecilia reticulata) LC50 (96hr) 320 mg/L (OECD SIDS) Zebra fish (Danio rerio) NOEC (35d) >= 25.7 mg/L (OECD Guideline 210 , GLP) (TS : Ethylenediamintetraacetic acid, calcium disodium complex)

Water flea (Daphnia magna) EC50 (48hr) 140 mg/L, NOEC (21d) 25 mg/L (EEC Guideline XI/681/86, GLP) (TS: Ethylenediaminetetraacetic acid, disodium salt)

Green algae (Scenedesmus quadricauda) NOEC (24 d) 200 mg/L (ECHA)

### SECTION 13: DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

### SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated. DOT UN Number: Not Regulated.

# SECTION 15: REGULATORY INFORMATION

EINECS Number: 243-285-9

Benzyl Alcohol:

TSCA Inventory Status: Listed EINECS Number: 202-859-9 Canada DSL: Listed

Canada IDL: Identified under the Canadian Hazardous Products Act Ingredient Disclosure List: 0.1%.169(170)

**Edetate Disodium:** 

TSCA Inventory Status: Listed EINECS Number: 205-358-3 Canada DSL: Listed

# SECTION 16: ADDITIONAL INFORMATION

**HMIS Ratings**:

SDS Creation Date: January 08, 2009 SDS Revision Date: June 01, 2015

SDS Format:

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2015 Actio Corporation. All Rights Reserved.

Mesna Injection Fresenius Kabi USA, LLC Revision: 06/01/2015 Page 5 of 5